Meeting
2024 ASCO Genitourinary Cancers Symposium
Patient characteristics, treatment patterns, and outcomes among early adopters of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617): A real-world United States (US) study.
Authors
Xiao X. Wei
Dana-Farber Cancer Institute, Boston, MA
Xiao X. Wei , Daniel J. George , Jeetvan Patel , Jennifer Nguyen , Barinder Kang , Amrita Sawhney , Magdaliz Gorritz , Chi-Chang Chen , Queenie Paltanwale , Kainan Sun , Neal D. Shore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 81)
DOI
10.1200/JCO.2024.42.4_suppl.81
Abstract #
81
Poster Bd #
C16
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.
First Author: Rebecca Hassoun
Poster
2022 ASCO Annual Meeting
Treatment patterns and their impact on the outcome of patients with HR+/HER2+ metastatic breast cancer in a large real-world cohort.
First Author: Marcela Carausu
Poster
2019 Genitourinary Cancers Symposium
Whole blood FOLH1 mRNA expression and treatment response in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Edmond Michael Kwan
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world clinical outcomes of patients treated with Lu-177-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC): A single-institution experience.
First Author: Valeria Maldonado Grijalva